Anandamide induces cell death through lipid rafts in hepatic stellate cells
10.1111/j.1440-1746.2009.06122.x · doi-reference
Chronic oleoylethanolamide treatment decreases hepatic triacylglycerol level in rat liver by a PPARγ/SREBP-mediated suppression of fatty acid and triacylglycerol synthesis
10.3390/nu13020394 · doi-reference
Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells
10.18632/oncotarget.6466 · doi-reference
Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats
10.1016/j.jphs.2014.12.001 · doi-reference
The effect of oleoylethanolamide (OEA) add-on treatment on inflammatory, oxidative stress, lipid, and biochemical parameters in the acute ischemic stroke patients: randomized double-blind placebo-controlled study
10.1155/2022/5721167 · doi-reference
Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells
10.1124/mol.108.047035 · doi-reference
2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist, in various rat tissues during the evolution of experimental cholestatic liver disease
10.1016/j.plefa.2008.07.003 · doi-reference
Potentiation of anandamide effects in mesenteric beds isolated from bile duct-ligated rats: role of nitric oxide
10.1016/j.ejphar.2003.12.004 · doi-reference
Bile acid levels are increased in the liver of patients with steatohepatitis
10.1097/meg.0b013e3282f4710a · doi-reference
Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat
10.1053/gast.2002.30305 · doi-reference
The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives
10.1111/liv.12263 · doi-reference
Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications
10.1016/j.ddmec.2011.02.001 · doi-reference
Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice
10.1042/cs20130642 · doi-reference
Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase
10.1096/fj.06-7705com · doi-reference
Recent advances in the understanding of the role of the endocannabinoid system in liver diseases
10.1016/j.dld.2010.08.010 · doi-reference
Glutamate signaling in hepatic stellate cells drives alcoholic steatosis
10.1016/j.cmet.2019.08.001 · doi-reference
The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma
10.1016/j.envres.2023.115914 · doi-reference
Liver cancer epidemic in China: past, present and future
10.1016/j.semcancer.2010.11.002 · doi-reference
Cannabinoid receptor type I modulates alcohol-induced liver fibrosis
10.2119/molmed.2011.00149 · doi-reference
Pathobiology of liver fibrosis: a translational success story
10.1136/gutjnl-2014-306842 · doi-reference
Cannabinoid-2 receptor depletion promotes non-alcoholic fatty liver disease in mice via disturbing gut microbiota and tryptophan metabolism
10.1038/s41401-025-01495-w · doi-reference
Human liver fatty acid binding protein-1 T94A variant, nonalcohol fatty liver disease, and hepatic endocannabinoid system
10.1002/lipd.12008 · doi-reference
The liver as an endocrine organ: linking NAFLD and insulin resistance
10.1210/er.2019-00034 · doi-reference
Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome
10.1186/s13020-023-00729-5 · doi-reference
The epidemiology, pathogenesis and histopathology of fatty liver disease
10.1111/j.1365-2559.2011.04145.x · doi-reference
The endocannabinoid-alcohol crosstalk: recent advances on a bi-faceted target
10.1111/1440-1681.12967 · doi-reference
Hepatic cannabinoid signaling in the regulation of alcohol-associated liver disease
10.35946/arcr.v41.1.12 · doi-reference
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury
10.1096/fj.06-7451com · doi-reference
Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis
10.1189/jlb.0307180 · doi-reference
Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice
10.1016/j.nbd.2005.07.008 · doi-reference
Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry
10.1021/pr300683a · doi-reference
Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis
10.1136/gutjnl-2015-310212 · doi-reference
The endocannabinoid system in cholestasis
10.1016/j.dld.2011.05.005 · doi-reference
The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species
10.1096/fj.06-7717com · doi-reference
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis
10.1111/j.1478-3231.2009.02137.x · doi-reference
4-O’-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice
10.1007/s00109-017-1556-y · doi-reference
Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation
10.3390/ijms16047057 · doi-reference
Differential effect of interferon-alpha treatment on AEA and 2-AG levels
10.1016/j.bbi.2020.08.024 · doi-reference
Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis
10.1172/jci.insight.92989 · doi-reference
Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease
10.1053/j.gastro.2010.06.064 · doi-reference
